• Je něco špatně v tomto záznamu ?

Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma

I. Sirák, J. Petera, J. Hatlová, M. Vošmik, B. Melichar, J. Dvořák, V. Tyčová, Z. Zoul, M. Leško

. 2009 ; 56 (93) : 1213-1218.

Jazyk angličtina Země Řecko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11022418

BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of p53, p21 or p16 expression predicts response to preoperative chemoradiotherapy in locally advanced gastric carcinoma. METHODOLOGY: Thirty-six patients (cT2-4 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous 5-fluorouracil and weekly cisplatin. Expression of p53, p21 and p16 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level and/or finding of intense tumor regression in histopathologic examination. RESULTS: Seventeen patients responded to chemoradiation: 8 patients had pathologic complete response, 9 patients were downstaged. The multivariate analysis showed no significant influence of p53 (p = 0.76), p21 (p = 0.10) nor p16 (p = 0.70) expression upon tumor response. Response was found in 52% of patients with low, and in 40% of patients with high p53 staining (p = 0.21); in 54% of patients with low, and in 30% of patients with high p21 staining (p = 0.14); and in 48% of patients with low, and in 43% of patients with high p16 staining (p = 0.32). CONCLUSIONS: We found no significant influence of p53, p21 nor p16 expression upon response to preoperative chemoradiotherapy in gastric carcinoma.

000      
03666naa 2200601 a 4500
001      
bmc11022418
003      
CZ-PrNML
005      
20120501202137.0
008      
110729s2009 gr e Eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Sirák, Igor $7 xx0135409
245    10
$a Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma / $c I. Sirák, J. Petera, J. Hatlová, M. Vošmik, B. Melichar, J. Dvořák, V. Tyčová, Z. Zoul, M. Leško
314    __
$a Department of Oncology and Radiotherapy, Charles University Medical School and University Hospital, Hradec Kralove, Czech Republic. sirak@fnhk.cz
520    9_
$a BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of p53, p21 or p16 expression predicts response to preoperative chemoradiotherapy in locally advanced gastric carcinoma. METHODOLOGY: Thirty-six patients (cT2-4 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous 5-fluorouracil and weekly cisplatin. Expression of p53, p21 and p16 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level and/or finding of intense tumor regression in histopathologic examination. RESULTS: Seventeen patients responded to chemoradiation: 8 patients had pathologic complete response, 9 patients were downstaged. The multivariate analysis showed no significant influence of p53 (p = 0.76), p21 (p = 0.10) nor p16 (p = 0.70) expression upon tumor response. Response was found in 52% of patients with low, and in 40% of patients with high p53 staining (p = 0.21); in 54% of patients with low, and in 30% of patients with high p21 staining (p = 0.14); and in 48% of patients with low, and in 43% of patients with high p16 staining (p = 0.32). CONCLUSIONS: We found no significant influence of p53, p21 nor p16 expression upon response to preoperative chemoradiotherapy in gastric carcinoma.
590    __
$a bohemika - dle Pubmed
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a karcinom $x metabolismus $x patologie $x terapie $7 D002277
650    _2
$a rozdělení chí kvadrát $7 D016009
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a staging nádorů $7 D009367
650    _2
$a předoperační péče $7 D011300
650    _2
$a celková dávka radioterapie $7 D011879
650    _2
$a nádory žaludku $x metabolismus $x patologie $7 D013274
650    _2
$a Stomach Neoplasms $x th [Therapy]
650    _2
$a Tumor Markers, Biological $x me [Metabolism]
650    _2
$a Tumor Suppressor Protein p53 $x me [Metabolism]
650    _2
$a financování organizované $7 D005381
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Petera, Jiří, $d 1959- $7 xx0000229
700    1#
$a Hatlová, Jana. $7 xx0227931
700    1_
$a Vošmik, Milan, $d 1972- $7 xx0135408
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853
700    1_
$a Dvořák, Josef, $d 1966- $7 xx0072583
700    1_
$a Tyčová, Věra $7 xx0107794
700    1#
$a Zoul, Zdeněk. $7 xx0041328
700    1_
$a Leško, Michal, $d 1955-2019 $7 xx0063978
773    0_
$t Hepato-Gastroenterology $w MED00002025 $g Roč. 56, č. 93 (2009), s. 1213-1218 $x 0172-6390
910    __
$a ABA008 $b x $y 2
990    __
$a 20110802082559 $b ABA008
991    __
$a 20120501202203 $b ABA008
999    __
$a ok $b bmc $g 881793 $s 732345
BAS    __
$a 3
BMC    __
$a 2009 $x MED00002025 $b 56 $c 93 $d 1213-1218 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology
LZP    __
$a 2011-4B09/jvme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...